ArticleWorld journal of gastroenterology2006
Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumor.
Article in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 33 citations in OpenAlex.
- Ki-67 and Tumor Size in Small Bowel Tumors: Findings from an Exploratory Immunohistochemical Analysis.Life (Basel, Switzerland) · 2025Article
- Mutational characteristics of gastrointestinal stromal tumors: A single-center analysis of 302 patients.Oncology letters · 2021Article
- Clinicopathologic features and prognostic grouping of gastrointestinal stromal tumors (GISTs) in Pakistani patients: an institutional perspective.BMC research notes · 2018Article
- Gastrointestinal stromal tumours (GISTs): an insight into clinical practice with review of literature.Frontline gastroenterology · 2017Article
- Positive cyclin T expression as a favorable prognostic factor in treating gastric gastrointestinal stromal tumors.Molecular and clinical oncology · 2016Article
- Reactive nodular fibrous pseudotumor involving the gastrointestinal tract and mesentery: A case report and review of the literature.Oncology letters · 2015Article
- Simultaneous development of adenocarcinoma and gastrointestinal stromal tumor (GIST) in the stomach: case report.World journal of surgical oncology · 2012Article
- Rare gastric inflammatory myofibroblastic tumor in an adult woman: a case report with review of the literature.Case reports in medicine · 2012Article
- Clinicopathological and immunohistochemical features of gastointestinal stromal tumors.Cancer research and treatment · 2010Article
- Article
- Gastrointestinal stromal tumors: key to diagnosis and choice of therapy.Molecular diagnosis & therapy · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the clinicopathological features of gastrointestinal stromal tumor (GIST) and to study the reference indexes for malignancy.
methodsFifty-two cases of primary GIST were distinguished from a group of gastrointestinal mesenchymal tumors using a panel of antibodies such as CD117 and CD34 by immunohistochemical SP method. Their biological behaviors were analyzed using the expression of p21WAF1 and Bax in 52 cases of GIST.
resultsGrossly, the tumor size was between 1.5 cm and 13 cm (mean: 5.5 cm). Focal areas of hemorrhage, necrosis, or small cyst formation could be seen. Microscopically, the tumor was composed of spindle cells (20 cases), epithelioid cells (20 cases) and mixed cells (12 cases). Immunohistochemically, CD117 and CD34 showed diffuse strong positive expressions, the positive rates were 98.1% and 92.3%. SMA, S-100, NSE, NF and MBP showed focal positive expressions, the positive rates were 48.1%, 28.8%, 25%, 21.2% and 42.3% respectively. Vimentins were all positive desmin and CgA were all negative. In normal adult stomach and intestine, the immunoreactive staining for CD117 and CD34 showed immunoreactive interstitial cells of Cajal in myenteric neuroplexus. Among the 52 cases of GIST, 27 were positive for p21WAF1 (51.9%), 29 for Bax (55.8%). The expression of p21WAF1 and Bax had no significent difference with the localization, size, histological subtype of GIST, but had a significent difference with the histological grade (P = 0.000, respectively). p21WAF1 expression had a positive correlation to Bax expression (r = 0.461, P = 0.001, kappa = 0.459).
conclusionGIST has complicated arrangements and various cell types. Positivity of CD117 and CD34 is the most valuable factor in diagnosing GIST. Expression of p21WAF1 and Bax plays an important role in potential malignancy and malignancy rather than in benign GIST. p21WAF1 and Bax may be used as the markers in the assessment of GIST malignant potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.